Clinical data of COVID-19 infected patients

Objectives This study aimed to evaluate the clinical efficacy of Paxlovid in patients hospitalized with severe/critical COVID-19. Methods Data were acquired from patients with severe/critical COVID-19 diagnosed between December 2022 and January 2023 at a medical center in China. Patients were divided into the Paxlovid treatment group and the conventional treatment group. The association between Paxlovid and all-cause mortality of patients during hospitalization was evaluated using the COX regression model and inverse probability weighting method, respectively. The secondary endpoint was the improvement in patients’ lung imaging findings 1 week later. The odds ratio (OR) was estimated using logistic regression. Results A total of 158 eligible patients were enrolled, including 50 in-hospital deaths (50/98) in the Paxlovid group and 28 (28/60) in the conventional treatment group. The corrected hazard ratio for death was 0.51 (95% CI: 0.28–0.94, p = 0.031) and the inverse probability-weight..., , , # Clinical Data of COVID-19 Infected Patients [https://doi.org/10.5061/dryad.m63xsj49r](https://doi.org/10.5061/dryad.m63xsj49r) the data were mainly acquired from a large medical center in China, where the diagnosis and treatment of critical illness is one of its strengths. Clinical data was obtained by searching in the electronic medical record system. Departments included in the search were where COVID-19 cases were centralized for treatment in our center, such as the respiratory department, the isolation wards for COVID-19 cases, and the intensive care unit (ICU). Clinical data from patients diagnosed with severe or critical COVID-19 infection were continuously collected and included in this study, with a time frame ranging from December 1, 2022, to January 15, 2023, during which the Omicron infection had peaked in mainland China. ## Description of the data and file structure The electronic medical records of patients eligible for inclusion in this hospital were analyzed, with...### 研究目标 本研究旨在评估帕昔洛韦（Paxlovid）在住院治疗的重型/危重型新型冠状病毒肺炎（COVID-19）患者中的临床疗效。 ### 研究方法 本研究数据来源于中国某医疗中心2022年12月至2023年1月期间确诊的重型/危重型COVID-19患者。将患者分为帕昔洛韦治疗组与常规治疗组。分别采用COX回归模型与逆概率加权法，评估帕昔洛韦与患者住院期间全因死亡率的相关性。次要终点为患者1周后肺部影像学表现的改善情况。采用logistic回归估算比值比（OR）。 ### 研究结果 共计纳入158例符合入组标准的患者，其中帕昔洛韦组98例，院内死亡50例（50/98）；常规治疗组60例，院内死亡28例（28/60）。校正后死亡风险比为0.51（95%置信区间：0.28–0.94，P=0.031），逆概率加权……，，， # 新型冠状病毒肺炎感染患者临床数据 [https://doi.org/10.5061/dryad.m63xsj49r](https://doi.org/10.5061/dryad.m63xsj49r) 本研究数据主要来源于中国某大型医疗中心，该中心的重症诊疗为其优势领域之一。临床数据通过电子病历系统检索获取，检索涵盖本中心集中收治COVID-19患者的相关科室，包括呼吸内科、COVID-19隔离病房及重症监护室（ICU）。本研究连续收集2022年12月1日至2023年1月15日期间确诊为重型或危重型COVID-19感染的患者临床数据，该时段正是奥密克戎感染在中国大陆达到流行高峰的时期。 ## 数据与文件结构说明 对本医院符合入组标准的患者电子病历进行分析，……